Cell Therapy for Ischemic Heart Failure and Non Ischemic Heart Failure is under clinical development by Cell2Cure and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease). According to GlobalData, Phase II drugs for Coronary Artery Disease (CAD) (Ischemic Heart Disease) have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cell Therapy for Ischemic Heart Failure and Non Ischemic Heart Failure’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cell Therapy for Ischemic Heart Failure and Non Ischemic Heart Failure overview

Cell therapy is under development for the treatment of ischemic heart failure and non-ischemic heart failure. The therapeutic candidate comprises of allogeneic adipose tissue derived mesenchymal stromal or stem cells and administered through intracardial route. It is being developed based on ASC technology.

Cell2Cure overview

Cell2Cure is a biotherapeutic company developing ‘off-the-shelf’ adipose tissue derived mesenchymal stromal cell (ASC) products applied in a wide range of advanced-stage diseases with involvement of inflammation and immunological activity, blood circulatory disturbance, fibrosis and scar development. Cell2Cure is headquartered in Birkerod, Denmark.

For a complete picture of Cell Therapy for Ischemic Heart Failure and Non Ischemic Heart Failure’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.